From DNA marks to RNA control: A new clue to acute myeloid leukemia

Acute myeloid leukemia (AML) is a serious form of blood cancer characterized by the buildup of abnormal, immature blood cells in the bone marrow. A new study, conducted by researchers at the Josep Carreras Leukaemia Research Institute led by Dr. José Luis Sardina, has uncovered a connection between DNA chemical marks and RNA regulation in AML.

The research, published in the journal Science Advances, focuses on the gene TET2, which is frequently mutated in AML patients. TET2 produces a protein that regulates DNA methylation, contributing to the regulation of gene activity through a process known as epigenetics.

The study investigated how TET2 directs genetic programs that guide cell identity by examining its actions along DNA and its effects on DNA methylation, gene activity, and DNA organization. Researchers found that TET2 binds to specific regions within the AGO2 gene, a gene involved in RNA interference. AGO2 helps control the fate of RNA molecules, including their breakdown or conversion into proteins.

The researchers observed that TET2 removes DNA methylation marks in these regions, leading to increased expression of the AGO2 protein.

The findings suggest that AGO2 plays a role in coordinating myeloid cell identity with cellular programs that support cell growth. By reducing AGO2 levels, the study demonstrated that leukemia cells became less capable of establishing and maintaining the disease, as observed in mice. This discovery raises the possibility that AGO2 could be a potential therapeutic target in AML treatment.

However, it remains unclear whether targeting AGO2 would be safe and effective in patients. The study also found that increased DNA methylation at an AGO2 regulatory region is associated with TET2-mutant AML cases, further supporting the link between AGO2 regulation and AML.

These findings open up new avenues for investigating the role of AGO2 in leukemia development and explore the potential of targeting this protein for therapeutic purposes. Further research is needed to fully understand the mechanisms involved and to determine the clinical relevance of these findings for AML patients.